RxDoctor Payments DataLook up a doctor →

Mark Greenberger, MD

Urology · Memphis, TNNPI 1497860720

Payments from drug & device makers

$248,881in general payments, 2019–2025

Across 1,012 payments — averaging $245.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Triad Life Sciences Inc.$221K
  • Coloplast$5K
  • Medtronic$3K
  • Axonics, Inc.$2K
  • Teleflex LLC$2K
  • Dendreon Pharmaceuticals LLC$2K
  • plus $15K from 54 others

What the payments were for

  • Travel & lodging$8200%
  • Food & beverage$26,07610%
  • Education$8440%
  • Other$221,14289%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Triad Life Sciences Inc.6$221,154
Coloplast233$4,713
Medtronic(2 entities)49$3,077
Axonics, Inc.94$1,637
Teleflex LLC19$1,630
Dendreon Pharmaceuticals LLC52$1,596
Astellas Pharma US Inc74$1,490
Sumitomo Pharma America, Inc.50$1,433
Boston Scientific42$1,424
Johnson & Johnson(2 entities)60$1,225
Endo Pharmaceuticals Inc.30$869
Urogen Pharma, Inc.27$772
Neotract Inc.10$758
Procept Biorobotics Corporation9$743
Pfizer24$530
Antares Pharma, Inc.24$418
Myriad Genetic Laboratories, Inc.11$328
C. R. Bard, Inc. & Subsidiaries13$324
Merck13$270
Ambu Inc.7$258
Biotissue Holdings Inc.6$254
Tolmar, Inc.9$254
Myovant Sciences Inc.10$240
AstraZeneca8$233
Tolmar Pharmaceuticals, Inc.3$191
Bayer11$182
AbbVie(2 entities)10$160
Novartis7$151
Angiodynamics, Inc.1$150
Ferring Pharmaceuticals Inc.9$148
Endo USA, Inc.6$147
Rochester Medical Corporation8$147
SRS Medical Systems, Inc.1$146
Blue Earth Diagnostics7$136
Cook Medical LLC3$127
Profound Medical Corp.1$107
Bard Access Systems, Inc.1$106
Clarus Therapeutics Inc.6$97
KARL Storz Endoscopy-america1$94
Tempus AI, Inc4$92
Photocure Inc1$87
Laborie Medical Technologies Corp.5$86
Olympus America Inc.4$81
Sun Pharmaceutical Industries Inc.3$75
Accord Healthcare, Inc.3$74
Amgen4$69
Urovant Sciences Inc4$61
Travere Therapeutics, Inc.3$59
Halozyme Inc2$46
Baxter Healthcare1$37
Foundation Medicine, Inc.2$32
Agiliti Surgical, Inc.1$28
Integra Lifesciences Corporation1$25
Smith+Nephew1$24
EDAP Technomed Inc3$24
Otsuka America Pharmaceutical, Inc.1$23
Immunitybio, Inc.1$23
Novo Nordisk1$22
Kowa Pharmaceuticals America, Inc.1$22
Cumberland Pharmaceuticals, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$248,881 in reported general payments places this provider in the 90th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,014,921
Medicare patients
1,698
Services billed
60,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide358$4,898,664
ErleadaApalutamide71$983,201
NubeqaDarolutamide71$907,702
OrgovyxRelugolix283$721,336
MyrbetriqMirabegron581$404,304
TalzennaTalazoparib Tosylate19$338,057
GemtesaVibegron483$328,183
LynparzaOlaparib15$256,464
Abiraterone Acetate60$130,922
XgevaDenosumab31$98,714
ProliaDenosumab20$32,385
Tamsulosin Hcl1,836$26,883
Fesoterodine Fumarate ErFesoterodine Fumarate137$17,430
Testosterone Cypionate269$15,627
Dutasteride443$14,851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,490$5,302,968939 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$1,433$1,049,519766 claims
Johnson & JohnsonErleada$1,225$983,20171 claims
BayerNubeqa$182$907,70271 claims
PfizerTalzenna$530$338,05719 claims
AstraZenecaLynparza$233$256,46415 claims
AmgenXgeva, Prolia$69$131,09951 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 276 urology providers in Tennessee.

Other urology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →